ليتروزول تيڤع

Nazione: Israele

Lingua: arabo

Fonte: Ministry of Health

Principio attivo:

LETROZOLE 2.5 MG

Commercializzato da:

TEVA PHARMACEUTICAL INDUST.LTD

Codice ATC:

L02BG04

Forma farmaceutica:

TABLETS

Via di somministrazione:

PER OS

Prodotto da:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Gruppo terapeutico:

LETROZOLE

Indicazioni terapeutiche:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Data dell'autorizzazione:

2010-01-01